Literature DB >> 30222610

Conservative Management of Placenta Accreta Spectrum.

Loïc Sentilhes1, Gilles Kayem2, Robert M Silver3.   

Abstract

The purpose of this review was to assist obstetricians and gynecologists in considering the most appropriate conservative treatment option to manage women with placenta accreta spectrum according to their individual need and local expertise of the heath care team. The issue is challenging, as the quality of evidence with regard to efficacy is poor, and is mainly based on retrospective studies with limited sample size.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30222610     DOI： 10.1097/GRF.0000000000000395

Source DB:  PubMed          Journal:  Clin Obstet Gynecol        ISSN： 0009-9201            Impact factor:   2.190


  5 in total

1.  Local uterine resection with Bakri balloon placement in placenta accreta spectrum disorders.

Authors:  Emin Üstünyurt
Journal:  Turk J Obstet Gynecol       Date:  2020-07-29

2.  CCN3 Signaling Is Differently Regulated in Placental Diseases Preeclampsia and Abnormally Invasive Placenta.

Authors:  Liyan Duan; Manuela Schimmelmann; Yuqing Wu; Beatrix Reisch; Marijke Faas; Rainer Kimmig; Elke Winterhager; Angela Köninger; Alexandra Gellhaus
Journal:  Front Endocrinol (Lausanne)       Date:  2020-11-16       Impact factor: 5.555

3.  MRI-Based Radiomics Analysis for Intraoperative Risk Assessment in Gravid Patients at High Risk with Placenta Accreta Spectrum.

Authors:  Caiting Chu; Ming Liu; Yuzhen Zhang; Shuhui Zhao; Yaqiong Ge; Wenhua Li; Chengjin Gao
Journal:  Diagnostics (Basel)       Date:  2022-02-14

4.  Conservative management of abnormally invasive placenta complicated by local hyperfibrinolysis and beginning disseminated intravascular coagulation.

Authors:  C Biele; L Kaufner; A Schwickert; A Nonnenmacher; K von Weizsäcker; M Z Muallem; W Henrich; T Braun
Journal:  Arch Gynecol Obstet       Date:  2020-08-18       Impact factor: 2.344

5.  Reply to: "Hysterectomy versus continuing conservative management: which is better for disseminated intravascular coagulation?"; Shinya Matsuzaki, MD, PhD, Yoshikazu Nagase, MD, Masayuki Endo, MD, PhD, Tadashi Kimura, MD, PhD.

Authors:  C Biele; L Kaufner; A Nonnenmacher; K von Weizsäcker; M Z Muallem; W Henrich; Thorsten Braun
Journal:  Arch Gynecol Obstet       Date:  2021-02-05       Impact factor: 2.344
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.